CHAPEL HILL -- To get the extra energy they need to fuel their uncontrolled growth, cancer cells break down some of their own parts for fuel - a process known as autophagy, or "self-eating." Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center found a possible therapeutic strategy to block self-eating in one of the deadliest cancers, as well as to cut off the tumor's other energy sources.
Losing just one night of sleep led to an immediate increase in beta-amyloid, a protein in the brain associated with Alzheimer's disease, according to a small, new study by researchers at the National Institutes of Health. In Alzheimer's disease, beta-amyloid proteins clump together to form amyloid plaques, a hallmark of the disease.
ILC 2018: Ongoing Phase 2 studies of tropifexor and seladelpar report promising preliminary efficacy, safety and tolerability results, paving the way for longer-term studies in patients with primary biliary cholangitis
13 April 2018, Paris, France: The fibroblast growth factor 19 (FGF19) engineered analogue, NGM282, inhibits bile acid synthesis, decreases markers of hepatic inflammation, and significantly improves markers of fibrosis in patients with primary sclerosing cholangitis (PSC), according to the results of a Phase 2, multicentre, randomized, double-blind, placebo-controlled study reported today. The study, which involved 62 patients with PSC diagnosed according to EASL criteria,7 offers hope of a new medical treatment for a condition in which effective drug therapies are currently limited.8
13 April 2018, Paris, France: Deep-learning approaches to pattern recognition in liver biopsy samples have moved one step closer to clinical application, with a new study reporting a good correlation between an automated image analysis system and an expert reviewer for the identification of key markers of disease activity in a pre-clinical model of non-alcoholic steatohepatitis (NASH).
Cloud computing, "exhausted" T cells, breast cancer risk in childhood cancer survivors and clinical trial design for CAR-T therapy in solid tumors are among the topics St. Jude Children's Research Hospital investigators will discuss at the five-day American Association for Cancer Research annual meeting that begins Saturday, April 14, in Chicago.
About a year and a half ago, a 6-year-old boy arrived at Children's Emergency Department after accidently removing his own gastrointestinal feeding tube. He wasn't a stranger to Children's National Health System: This young patient had spent plenty of time at the hospital since birth. Diagnosed in infancy with an intestinal pseudo-obstruction, a rare condition in which his bowels acted as if there were a blockage even though one was not present, parts of his intestine died and had been removed through multiple surgeries.
First study to show 'owls' have higher risk of mortality
Switch to daylight savings time is much harder for them
They suffer from more diseases and disorders than morning larks
Employers should allow greater flexibility in working hours
Consider abolishing daylight savings time, scientists say
PARIS, 12 April 2018 - An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the
Geneva, Switzerland, 12 April 2018 - Alectinib provides longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC), according to results from the ALEX trial (1) presented at the ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland. (2)